BioAge Labs, Inc. (BIOA) · Oct 2, 2026 · Other events

BioAge DME Phase 2 filing repeats September start; 2027 data unchanged

No new info

BioAge’s DME Phase 2 filing confirms dosing and trial design, but adds little beyond the September 8 announcement or the existing 2027 data timeline.

BioAge is a clinical-stage biotechnology company building BGE-102, an oral, brain-penetrant NLRP3 inhibitor, across cardiometabolic and retinal diseases; its nearer-term story is execution on two Phase 2 programs, QUELL-CV and QUELL-DME.

The DME trial has begun, but the milestone was already public. The filing confirms that the first participant was dosed in QUELL-DME, a roughly 180-person randomized Phase 2 study of BGE-102 in diabetic macular edema. 〔0〕 That same start was publicly announced on September 8, 2026, so the October 2 filing is confirmation rather than a fresh clinical surprise.

The design gives BioAge two shots at proving the drug’s role, not efficacy yet. Participants are split among anti-VEGF plus placebo, anti-VEGF plus BGE-102, and BGE-102 alone with a sham injection. 〔1〕 That structure tests both whether BGE-102 can work as an oral standalone treatment and whether it can improve standard anti-VEGF therapy, but the filing contains no patient outcomes or safety readout.

The timeline is unchanged and remains distant. The primary endpoint is change in best-corrected visual acuity at week 12, with topline results expected in the second half of 2027. 〔2〕 That leaves QUELL-CV’s expected second-half 2026 data as the next meaningful clinical test of BGE-102, not this filing.

Bottom line: The business is progressing on schedule, but this October 2 filing does not materially change BioAge’s story because the DME start, design, and 2027 readout timing were already disclosed on September 8, 2026.

What to watch next

QUELL-CV topline data, second half 2026

Original filing on SEC EDGAR

More BioAge Labs, Inc. news

BioAge DME Phase 2 filing repeats September start; 2027 data unchanged | BIOA Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.